The poultry industry plays a major role in the emergence and spread of foodborne zoonotic diseases, particularly those associated with antibiotic-resistant bacteria. These diseases pose substantial global public health challenges, and the increasing development of antimicrobial resistance further intensifies these concerns. In response, scientific efforts have expanded to develop and implement innovative technologies capable of mitigating the rising prevalence of multidrug-resistant (MDR) microorganisms. Therapeutic bacteriophage supplementation has regained significant attention because it can selectively lyse specific bacteria, is cost-effective to produce, offers environmentally favorable characteristics, and provides several advantages over conventional antibiotics. Experimental studies have demonstrated that phage therapy is both safe and effective for controlling poultry-associated enteric pathogens. Phages can be applied at various stages of the poultry production chain, from rearing to processing and distribution, using multiple delivery strategies. Despite certain limitations, the targeted and well-regulated application of phage cocktails offers considerable potential as an alternative to antibiotics for managing MDR infections. The success of bacteriophage therapy depends on several factors, including the timing of administration, dosage, delivery method, and its integration with other therapeutic approaches. Therefore, developing a comprehensive understanding of bacteriophage utilization in poultry production is both timely and necessary. This review examines the applications, constraints, and future opportunities of phage therapy within the commercial poultry industry, with particular emphasis on the mechanisms through which bacteriophages control bacterial infections.
Batool et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: